Reuters exclusively reports Sanofi to enroll thousands for its coronavirus vaccine trials

Reuters exclusively reported that French drugmaker Sanofi said it plans to enroll thousands of subjects globally for trials of an experimental vaccine for the coronavirus it is developing with GlaxoSmithKline Plc, and that it has started to discuss advanced purchases with several countries. Sanofi is working on two vaccine projects to prevent COVID-19 and said it is exploring several manufacturing options, including fresh collaborations to ensure it can meet demand if either program is successful.